Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients.

Journal of medical virology - 1 Dec 2016

Helal Gouda Kamel, Gad Magdy Abdelmawgoud, Abd-Ellah Mohamed Fahmy, Eid Mahmoud Saied

Abstract excerpt

The therapeutic effect of pegylated interferon (peg-IFN) alfa-2a combined with ribavirin (RBV) on chronic hepatitis C Egyptian patients is low and further efforts are required to optimize this therapy for achievement of higher rates of virological response. This study aimed to evaluate the safety and efficacy of hydroxychloroquine (HCQ) in combination with pegylated interferon plus ribavirin on early virological...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Egypt
Share to Drug Administration Schedule

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Hepatitis C, Chronic

Share to Hydroxychloroquine

Share to Interferon-alpha

Share to Polyethylene Glycols

Share to Ribavirin

Source

Open in PubMed Open full text

Identifiers

PMID: 27183377
DOI: 10.1002/jmv.24575
PMCID: PMC7167065

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients.PMID 27183377Read ↗

Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.Semantic proximity Read ↗

A randomized trial of 24 versus 48 weeks of peginterferon alpha-2a plus ribavirin in Egyptian patients with hepatitis C virus genotype 4 and rapid viral response.Semantic proximity Read ↗

Hepatitis C Viral Kinetic Changes in a Retrospective Cohort Study of Chronic Hepatitis C Virus Egyptian Patients on Pegylated Interferon and Ribavirin Therapy.Semantic proximity Read ↗

Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil.Semantic proximity Read ↗

Effectiveness of first-wave protease inhibitors in hepatitis C virus genotype 1 infection: a multicenter study in Brazil.Semantic proximity Read ↗

Treatment outcome in chronic hepatitis C infection: a four years survey among Iranian patients.Semantic proximity Read ↗

Hepatitis C treatment: shorter and better?Semantic proximity Read ↗

End-of-Treatment-Response in patients treated for hepatitis C virus with standard interferon and ribavirin based on viral load.Semantic proximity Read ↗

The Effect of Peginterferon Alpha-2a vs. Peginterferon Alpha-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian StudySemantic proximity Read ↗

Factors influencing the response of interferon therapy in chronic hepatitis C patients.Semantic proximity Read ↗

Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4.Semantic proximity Read ↗

Ribavirin in the treatment of hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.